Chris Holden

I'm Chris, and This is My Blog

CEO Clay Siegall’s Success in Innovative Cancer Research

by Chris Holden - January 20th, 2017.
Filed under: Cancer Research.

Cancer affects patients every year and is a disease which is a mystery to many. After witnessing the treatment and passing of his own father from brain cancer though, Clay B. Siegall, who was originally pursuing an MD, decided to switch to a PhD in genetics from George Washington University to change up the methodical ways of cancer research. He developed a passion for helping patients which influenced him to build a company with more drive and innovation than other cancer research companies today. With extensive experience as a scientist in targeted cancer therapies such as previously working with Bristol Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, and National Institutes of Health, Siegall has been able to advance research methods as we know it. Through Siegall’s determination he has become the co-founder of Seattle Genetics which focuses on rigorous research and drug development practices. He became the President, Chief Executive Officer and Chairman of the Board guiding the company to the top in developing anti-body drug conjugates (ADC) for the treatment of cancer as well as led Seattle Genetics into multiple strategic licenses for its ADC technology which include Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, all of which has generated more than $300 million to date.

Siegall’s passion for his patients has always driven him to focus more on the research of a product rather than the manufacturing of it: “My goal in the world is to treat cancer patients and do better than what we’re doing today with targeted drugs, and I love that I wake up every day and I’m excited about it,” Siegall said. “I’m not just saying that. It’s what I do. I’ve been doing it for 30 years.” With a man as passionate as Siegall, cancer research can and will become more advanced than society has known it to be: “Our goal is to be an independent, self-sustaining company that’s making the difference in the lives of cancer patients with innovative targeted therapies,” Siegall said. “We’re trying to build as strong a company as we can.”

Leave a Reply

You must be logged in to post a comment.